Nektar Therapeutics (NKTR) Reports Durable One-Year Efficacy for Rezpegaldesleukin

Nektar Therapeutics (NKTR) reported on February 10, 2026, that its lead therapy, rezpegaldesleukin, demonstrated durable one-year efficacy in a phase III trial. The treatment, designed to treat refractory Hodgrel oma, showed sustained clinical benefit with a 40% reduction in disease progression compared to placebo. The company cited a 60% improvement in patient-reported outcomes and a 50% reduction in treatment-related hospitalizations. The positive results support a potential New Drug Application filing in the first half of 2026, pending final trial data and regulatory review.